We love to hear from our listeners. Send us a message.

Becoming a biotech CEO wasn't on Paul Romness' bingo card. He'd forged his place in the biopharma industry as a foremost public and policy affairs expert. Thirteen years at J&J, more than 5 at Amgen, and half a dozen at Boehringer Ingelheim had earned him the right to coast into a consulting gig that would enable him to finish out his career on his terms. 

Then his daughter's best friend Olivia, a teenage girl and neighbor he'd watched grow up, was diagnosed with osteosarcoma. 

The ensuing journey, now in its seventh year, put Romness in the position of CEO and Chair of OS Therapies. It's a company formed through a combination of circumstance, determination, and ingenuity that's now shepherding its HER2 and tunable ADC therapeutics through mid-late-stage clinical trials. On this episode of the Business of Biotech, we dig into the building blocks of an unanticipated biotech startup. We'll learn how Romness leaned into his personal and professional communities to build a company that's now addressing unmet patient need in osteosarcoma and cancers of the breast, esophagus, lung, and pancreas. And we'll get an update on Olivia, who's now in med school at Columbia University and serving on the OS Therapies Board of Directors. 

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceconnect.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/